Edward Erickson, Ph.D
Dr. Erickson focuses primarily on providing strategic advice on the viability of new pharmaceuticals, and how to bring them to the U.S. market. He offers decades of R&D, business and regulatory experience. After receiving his Ph.D. in Organic Chemistry with an emphasis on Rational Drug Design, Ed began his healthcare career as a medicinal chemist with Riker Laboratories.
After Riker’s acquisition by 3M, Ed progressed through a series of R&D and general management positions – ending his 3M career as Vice President, Drug Delivery Systems. Following retirement, Ed has been active as a consultant and board member with a variety of pharmaceutical start-ups.
Highlights from Ed’s 3M career include managing the drug discovery team which first identified Imiquimod (Aldara) – a novel immune modulator – then as head of global R&D, managing its development and regulatory approval. During this time, he was also responsible for the R&D effort to replace CFC propellants with HFCs in 3M’s pharmaceutical inhalers. Ed then became R&D executive director for 3M’s Life Science Sector, which included managing the hearing health and veterinarian businesses. Next, he became Vice President, Medical-Surgical Division, where he focused on developing infection control products. Later, Ed finished his 3M career with a divisional restructuring effort, separating its drug delivery activities from its ethical pharmaceutical business.
Dr. Erickson is not an attorney and does not practice law.